From Financial Modeling Prep: 2024-10-30 13:52:00

Biogen (NASDAQ:BIIB) exceeded Q3 earnings expectations with $4.08 EPS, beating estimates of $3.77. Revenue of $2.47 billion surpassed the $2.43 billion consensus. The multiple sclerosis segment generated $1.05 billion in revenue, while sales of Alzheimer’s drug Leqembi reached $67 million, up from $40 million in the prior quarter. Full-year 2024 EPS guidance was raised to $16.10-$16.60, above the $16.19 consensus at the midpoint, with a low-single-digit revenue decline expected for 2023. Core pharmaceutical revenue is forecasted to remain flat.



Read more at Financial Modeling Prep:: Biogen Posts Q3 Earnings Beat and Raises 2024 Guid…